Skip to main content
. 2021 Apr 7;26(6):1073–1082. doi: 10.1007/s10147-021-01899-8

Fig. 2.

Fig. 2

Best percentage change from baseline in target lesion size for patients receiving treatment with durvalumab + EP or EP. Target lesion size based on site investigator assessment according to RECIST v1.1 Dashed reference lines at − 30% and + 20% indicate thresholds for partial response and disease progression, respectively